Hoersholm, Denmark, November 7th, 2015 Medical Prognosis Institute A/S (MPI.CO) has, in collaboration with Faculty of Health and Medical Sciences, University of Copenhagen, Faculty of Health, Aarhus University, Department of Oncology, Rigshospitalet, Copenhagen, Intomics, Copenhagen, Oncology Venture AB, Hoersholm, Saniona AB, Copenhagen and Faculty of Health, University of Southern Denmark, Odense, published a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, announcing the establishment of a novel and unique cell line based drug screening platform for cancer treatment.
The consortium has initiated the establishment of DEN50-R, a novel and unique cell line based drug screening platform within cancer treatment. The NCI60 cell line panel is mostly derived from patients with no medical treatment. Over the years, the panel has been of significant value in contributing to the identification of new molecular mechanisms involved in cancer progression, and in creating new anti-cancer drugs. Early clinical trials of anti-cancer drugs most often recruit patients who have failed several different prior treatments. Therefore, there has been a need to develop a platform built on the concept underlying the NCI60 cell line panel, and extend it to allow testing of potential new drugs in the setting of drug resistance.
“Our results with translating Drug Response Prediction from the NCI60 panel are very positive and the current academic project may add more value to this successful approach and we look forward to further collaboration“, says Adjunct professor Peter Buhl Jensen, M.D., CEO of MPI.
Link to poster
About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
For further information, please contact
Peter Buhl Jensen, CEO
e-mail: [email protected]
Cell Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
